It's Case C-414/11 Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon and it comes all the way from the Polimeles Protodikio Athinon (Greece). [read post]

Yesterday the IPKat celebrated the fact that two extra days were given to anyone who wants to advise the UK government whether -- and how -- to intervene in  Case C-414/11 Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon , a Greek reference for a preliminary ruling by the Court of Justice of the European Union on some TRIPS-related issues (see his earlier post… [read post]

(IP Dragon) Patent strategies for foreign R&D work in China (Philip Brooks' Patent Infringement Updates) All clichés but still true: Intellectual Property Rights enforcement in China leaves room for improvement (IP Dragon) Recognition and protection of well-known trade marks (International Law Office) Revised Chinese patent law aims at quality, compulsory licensing (Intellectual Property Watch) Zen and the art of intellectual property in China (IP Dragon)   Colombia… [read post]

: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]